Friday, January 24, 2020 12:06:30 PM
PuraStat may be primitive relative to AC5 (your basis for characterization?), I have no opinion. I do know that AC5 has not been commercialized in the US despite having marketing authorization for last 13 months (Dec 2018). If AC5 is a leap forward in clinical care, what's holding up the market introduction? PERHAPS introducing an endoscopic hemnostat for GI procedures would be a way to go. As said poreviously, AC5 technology seems to have potential, up to management to do something with it.
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM